BioLife Solutions Inc.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
IPO Year:
Exchange: NASDAQ
Website: biolifesolutions.com
Recent Analyst Ratings for BioLife Solutions Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/30/2024 | $29.00 | Buy | H.C. Wainwright |
| 4/4/2024 | $22.00 | Buy | Jefferies |
| 7/11/2023 | $29.00 | Buy | Craig Hallum |
| 4/25/2022 | $28.00 | Perform → Outperform | Oppenheimer |
| 10/19/2021 | $61.00 | Buy | B. Riley Securities |
| 10/15/2021 | $64.00 | Outperform | Cowen |
| 8/13/2021 | $50.00 → $60.00 | Overweight | Keybanc |
BioLife Solutions Inc. Press Releases
Fastest customizable press release news feed in the world
BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair
BOTHELL, Wash., March 18, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. "Cathy is a highly qualified financial professional with substantial expertise in audits, risk an
BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results
Cell Processing revenue up 7% sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12% over prior year to $73.5 million GAAP gross margin of 60% and non-GAAP adjusted gross margin of 63% for the fourth quarter GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million, or 18% of total revenue for the fourth quarter Expects 2025 Cell Processing revenue of $86.5 to $89.0 million, up 18% to 21% over 2024 and total revenue of $95.5 to $99.0 million, up 16% to 20% over 2024 Conference call begins at 8:00 a.m. Eastern time today BOTHELL, Wash., March 3, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife"
BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025
BOTHELL, Wash., Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. The Company will host a conference call and live webcast at 8:00am ET (5:00am PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relations page of
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations
Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million Unaudited revenue for FY2024 from Cell Processing of $73.5 million, exceeded the high end of previously raised guidance BOTHELL, Wash., Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced 2024 fourth quarter and full year preliminary unaudited revenue from continuing operations. Roderick de Greef, Chairman and CEO, commen
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is
BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary
Completes the Company's strategic move away from capital equipment businesses BOTHELL, Wash., Nov. 14, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ("Custom Biogenic Systems" or "CBS"), for $6.1 million in cash. "We have now completed the divestiture of all our freezer and related businesses, which began with the sale of Global Cooling
BioLife Solutions Reports Third Quarter 2024 Financial Results
Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023 GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20% Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of SciSafe divestiture Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services fo
BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary
Strategic divestiture heightens focus on proprietary, higher-margin cell processing products All-cash transaction fortifies balance sheet BOTHELL, Wash., Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, announces the sale of its wholly owned biostorage subsidiary SciSafe Holdings, Inc. ("SciSafe") for $73 million in cash. SciSafe generated approximately $10.4 million in revenue for the six months ended June 30, 2024.
BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024
BOTHELL, Wash., Oct. 31, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2024 financial results will be released after market close on Tuesday, November 12, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast
BioLife Solutions Reports Second Quarter 2024 Financial Results
Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader bio
BioLife Solutions Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright initiated coverage on BioLife Solutions with a new price target
H.C. Wainwright initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $29.00
Jefferies initiated coverage on BioLife Solutions with a new price target
Jefferies initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $22.00
Craig Hallum initiated coverage on BioLife Solutions with a new price target
Craig Hallum initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $29.00
BioLife Solutions upgraded by Oppenheimer with a new price target
Oppenheimer upgraded BioLife Solutions from Perform to Outperform and set a new price target of $28.00
B. Riley Securities initiated coverage on BioLife Solutions with a new price target
B. Riley Securities initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $61.00
Cowen resumed coverage on BioLife Solutions with a new price target
Cowen resumed coverage of BioLife Solutions with a rating of Outperform and set a new price target of $64.00
Keybanc reiterated coverage on BioLife Solutions with a new price target
Keybanc reiterated coverage of BioLife Solutions with a rating of Overweight and set a new price target of $60.00 from $50.00 previously
BioLife Solutions downgraded by The Benchmark Company
The Benchmark Company downgraded BioLife Solutions from Buy to Hold
BioLife Solutions downgraded by Benchmark
Benchmark downgraded BioLife Solutions from Buy to Hold
BioLife Solutions upgraded by Benchmark with a new price target
Benchmark upgraded BioLife Solutions from Hold to Buy and set a new price target of $54.00
BioLife Solutions Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Casdin Partners Master Fund, L.P. bought $10,374,976 worth of shares (927,165 units at $11.19) (SEC Form 4)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
BioLife Solutions Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Chief Human Resources Officer Aebersold Sarah was granted 37,068 shares, increasing direct ownership by 76% to 85,865 units (SEC Form 4)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
Director Duross Amy was granted 6,876 shares and sold $140,575 worth of shares (5,632 units at $24.96), increasing direct ownership by 4% to 30,687 units (SEC Form 4)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
Director Coste Catherine was granted 5,701 shares (SEC Form 4)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
Director Hunt Anthony was granted 6,876 shares (SEC Form 4)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
Director Moore Timothy L. was granted 6,876 shares, increasing direct ownership by 23% to 36,773 units (SEC Form 4)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
SEC Form 3 filed by new insider Coste Catherine
3 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
Chief Quality and Operations Foster Karen A. was granted 48,810 shares, increasing direct ownership by 32% to 203,722 units (SEC Form 4)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
Director Ellingson Rachel was granted 6,876 shares, increasing direct ownership by 16% to 49,825 units (SEC Form 4)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
Amendment: Chief Human Resources Officer Aebersold Sarah sold $68,561 worth of shares (2,695 units at $25.44), decreasing direct ownership by 5% to 48,797 units (SEC Form 4)
4/A - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
EVP & Chief Scientific Officer Mathew Aby J. was granted 59,564 shares, increasing direct ownership by 23% to 320,165 units (SEC Form 4)
4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)
BioLife Solutions Inc. SEC Filings
BioLife Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
SEC Form 10-K filed by BioLife Solutions Inc.
10-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
BioLife Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
BioLife Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
SEC Form 10-Q filed by BioLife Solutions Inc.
10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
BioLife Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
SEC Form 10-Q filed by BioLife Solutions Inc.
10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)
BioLife Solutions Inc. Leadership Updates
Live Leadership Updates
BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair
BOTHELL, Wash., March 18, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. "Cathy is a highly qualified financial professional with substantial expertise in audits, risk an
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is
BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors
Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash., Aug. 25, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six. Moore brings more than 30 years of broad-based leadership experience in biopharmaceutical manufacturing and operations.
BioLife Solutions Appoints Joydeep Goswami, MBA, PhD to Board of Directors
BOTHELL, Wash., Sept. 20, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that Joydeep Goswami, Chief Strategy and Corporate Development Officer at Illumina, will join its board of directors on October 1, 2021. In his role, he is responsible for driving planning, strategic partnerships, and acquisitions. Mr. Goswami replaces Andrew Hinson, who has retired from the board. Mik
BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors Rinda K. Sama and Andrew G. Hinson to Its Board of Directors
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company's chairman and named Rinda K. Sama and Andrew G. Hinson to its board of directors. Mr. Cohen has over 40 years' experience leading and guiding a variety of private and publicly traded life science companies as an executive and board member. Cohen, an accredited public company director, currently serves as the CEO and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX). In addition, two other accredited public company directors and experienced life science execu
BioLife Solutions Appoints Two New Independent Board Directors
BOTHELL, Wash., April 6, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has appointed Amy DuRoss, chief executive officer of Vineti, and Rachel Ellingson, senior vice president and chief strategy officer at Zimmer Biomet to its board of directors effective immediately. Mike Rice, BioLife CEO, commented, "We are very pleased to welcome Amy and Rachel as new independent directors to BioLife's board. They join BioLife at an exciting time. The addition of these directors complements our existing bo
BioLife Solutions Inc. Financials
Live finance-specific insights
BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results
Cell Processing revenue up 7% sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12% over prior year to $73.5 million GAAP gross margin of 60% and non-GAAP adjusted gross margin of 63% for the fourth quarter GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million, or 18% of total revenue for the fourth quarter Expects 2025 Cell Processing revenue of $86.5 to $89.0 million, up 18% to 21% over 2024 and total revenue of $95.5 to $99.0 million, up 16% to 20% over 2024 Conference call begins at 8:00 a.m. Eastern time today BOTHELL, Wash., March 3, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife"
BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025
BOTHELL, Wash., Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. The Company will host a conference call and live webcast at 8:00am ET (5:00am PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relations page of
BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary
Completes the Company's strategic move away from capital equipment businesses BOTHELL, Wash., Nov. 14, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ("Custom Biogenic Systems" or "CBS"), for $6.1 million in cash. "We have now completed the divestiture of all our freezer and related businesses, which began with the sale of Global Cooling
BioLife Solutions Reports Third Quarter 2024 Financial Results
Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023 GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20% Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of SciSafe divestiture Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services fo
BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary
Strategic divestiture heightens focus on proprietary, higher-margin cell processing products All-cash transaction fortifies balance sheet BOTHELL, Wash., Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, announces the sale of its wholly owned biostorage subsidiary SciSafe Holdings, Inc. ("SciSafe") for $73 million in cash. SciSafe generated approximately $10.4 million in revenue for the six months ended June 30, 2024.
BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024
BOTHELL, Wash., Oct. 31, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2024 financial results will be released after market close on Tuesday, November 12, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast
BioLife Solutions Reports Second Quarter 2024 Financial Results
Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader bio
BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024
BOTHELL, Wash., July 25, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, lo
BioLife Solutions Reports First Quarter 2024 Financial Results
Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands from 40% to 53% and adjusted EBITDA of $3.6 million or 13% ex-GCI freezers Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 9, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced financial results for the three months ended March 31, 2024 and affirmed its revenue guidance for 2024.
BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log o
BioLife Solutions Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)
SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)
SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SEC Form SC 13D/A filed by BioLife Solutions Inc. (Amendment)
SC 13D/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SEC Form SC 13G filed by BioLife Solutions Inc.
SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)
SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)
SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SEC Form SC 13G filed by BioLife Solutions Inc.
SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SEC Form SC 13G filed by BioLife Solutions Inc.
SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SEC Form SC 13G filed by BioLife Solutions Inc.
SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)
SEC Form SC 13D/A filed by BioLife Solutions, Inc. (Amendment)
SC 13D/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)